Biomarkers for pediatric pulmonary arterial hypertension - A call to collaborate

Frontiers in Pediatrics

Volumn 2, Issue FEB, 2014, Pages

  Colvin, Kelley L ^a,b,c   Dufva, Melanie J ^a,b   Delaney, Ryan P ^a,b   Dunbar Ivy, D ^d   Stenmark, Kurt R ^b   Yeager, Michael E ^a,b,c  

^a The University of Colorado Denver   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d CHILDREN S HOSPITAL   (United States)

Author keywords

Biomarkers; Echocardiography; Imaging; Magnetic resonance; Pediatric; Pulmonary arterial hypertension; Right ventricle

Indexed keywords

EID: 84912575374     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2014.00007     Document Type: Review

References (147)

1. De Wolf D. Clinical practice: pulmonary hypertension in children. Eur J Pediatr (2009) 168(5):515-22. doi: 10.1007/s00431-008-0920-x
2. Ivy D. Advances in pediatric pulmonary arterial hypertension. Curr Opin Cardiol (2012) 27(2):70-81. doi:10.1097/HCO.0b013e32835018cd
3. Oishi P, Datar SA, Fineman JR. Advances in the management of pediatric pulmonary hypertension. Respir Care (2011) 56(9):1314-39. doi:10.4187/respcare.01297
4. Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J (2011) 37(3):665-77. doi:10.1183/09031936.00056110
5. Kyle WB. Pulmonary hypertension associated with congenital heart disease: a practical review for the pediatric cardiologist. Congenit Heart Dis (2012) 7(6):575-83. doi:10.1111/chd.12012
6. Abman SH, Ivy DD. Recent progress in understanding pediatric pulmonary hypertension. Curr Opin Pediatr (2011) 23(3):298-304. doi:10.1097/MOP.0b013e3283464a52
7. Abman SH. Pulmonary hypertension in children: a historical overview. Pediatr Crit Care Med (2010) 11(2 Suppl):S4-9. doi:10.1097/PCC.0b013e3181c765f3
8. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest (2012) 122(12):4306-13. doi:10.1172/JCI60658
9. Rosenzweig EB, Widlitz AC, Barst RJ. Pulmonary arterial hypertension in children. Pediatr Pulmonol (2004) 38(1):2-22. doi:10.1002/ppul.20051
10. Gupta H, Ghimire G, Naeije R. The value of tools to assess pulmonary arterial hypertension. Eur Respir Rev (2011) 20(122):222-35. doi:10.1183/09059180.00006911
11. Rosenzweig EB, Barst RJ. Pulmonary arterial hypertension in children: a medical update. Indian J Pediatr (2009) 76(1):77-81. doi:10.1007/s12098-009-0032-2
12. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J (2007) 30(1):104-9. doi:10.1183/09031936.00092306
13. Barst RJ, Ivy DD, Foreman AJ, McGoon MD, Rosenzweig EB. Four-and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL registry). Am J Cardiol (2013) 113(1):147-55. doi:10.1016/j.amjcard.2013.09.032
14. van Loon RL, Roofthooft MT, Hillege HL, ten Harkel AD, van Osch-Gevers M, Delhaas T, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation (2011) 124(16):1755-64. doi:10.1161/CIRCULATIONAHA.110.969584
15. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart (2009) 95(4):312-7. doi:10.1136/hrt.2008.150086
16. Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation (2012) 125(1):113-22. doi:10.1161/CIRCULATIONAHA.111.026591
17. Fraisse A, Jais X, Schleich JM, di Filippo S, Maragnès P, Beghetti M, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis (2010) 103(2):66-74. doi:10.1016/j.acvd.2009.12.001
18. Fasnacht MS, Tolsa JF, Beghetti M, Swiss Society for Pulmonary Arterial Hypertension. The Swiss registry for pulmonary arterial hypertension: the paediatric experience. Swiss Med Wkly (2007) 137(35-36):510-3
19. Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet (2012) 379(9815):537-46. doi:10.1016/S0140-6736(11)61621-8
20. Rosenzweig EB, Barst RJ. Idiopathic pulmonary arterial hypertension in children. Curr Opin Pediatr (2005) 17(3):372-80. doi:10.1097/01.mop.0000163356.51027.c1
21. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest (2010) 137(2):376-87. doi:10.1378/chest.09-1140
22. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 69:89-95. doi:10.1067/mcp.2001.113989
23. Cracowski JL, Leuchte HH. The potential of biomarkers in pulmonary arterial hypertension. Am J Cardiol (2012) 110(6 Suppl):32S-8S. doi:10.1016/j.amjcard.2012.06.014
24. Barrier M, Meloche J, Jacob MH, Courboulin A, Provencher S, Bonnet S. Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension. Cell Mol Life Sci (2012) 69(17):2805-31. doi:10.1007/s00018-012-0950-4
25. Foris V, Kovacs G, Tscherner M, Olschewski A, Olschewski H. Biomarkers in pulmonary hypertension: what do we know? Chest (2013) 144(1):274-83. doi:10.1378/chest.12-1246
26. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 186(3):261-72. doi:10.1164/rccm.201201-0164OC
27. Guignabert C, Dorfmuller P. Pathology and pathobiology of pulmonary hypertension. Semin Respir Crit Care Med (2013) 34(5):551-9. doi:10.1055/s-0033-1356496
28. El Chami H, Hassoun PM. Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis (2012) 55(2):218-28. doi:10.1016/j.pcad.2012.07.006
29. Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 186(9):897-908. doi:10.1164/rccm.201202-0335OC
30. Heresi GA, Aytekin M, Hammel JP, Wang S, Chatterjee S, Dweik RA. Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension. Eur Respir J (2013). doi:10.1183/09031936.00164713
31. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation (2010) 122(9):920-7. doi:10.1161/CIRCULATIONAHA.109.933762
32. Yang D, Liu Z, Yang Z. Ghrelin and its relation with N-terminal brain natriuretic peptide, endothelin-1 and nitric oxide in patients with idiopathic pulmonary hypertension. Cardiology (2013) 124(4):241-5. doi:10.1159/000348368
33. Carlomagno G, Messalli G, Melillo RM, Stanziola AA, Visciano C, Mercurio V, et al. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. Int J Cardiol (2013) 168(2):1545-7. doi:10.1016/j.ijcard.2013.04.051
34. Uz O, Kardesoglu E, Tas D, Acar G, Isilak Z, Yiginer O, et al. CA-125 level is associated with right ventricular echocardiographic parameters in patients with COPD. South Med J (2011) 104(9):624-8. doi:10.1097/SMJ.0b013e318229a55c
35. Takeda Y, Takeda Y, Tomimoto S, Tani T, Narita H, Kimura G. Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. BMC Pulm Med (2010) 10:22. doi:10.1186/1471-2466-10-22
36. Monahan K, Scott TA, Su YR, Lenneman CG, Zhao DX, Robbins IM, et al. Reproducibility of intracardiac and transpulmonary biomarkers in the evaluation of pulmonary hypertension. Pulm Circ (2013) 3(2):345-9. doi:10.4103/2045-8932.114762
37. Saggar R, Sitbon O. Hemodynamics in pulmonary arterial hypertension: current and future perspectives. Am J Cardiol (2012) 110(6 Suppl):9S-15S. doi:10.1016/j.amjcard.2012.06.011
38. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J (2009) 30(20):2493-537. doi:10.1093/eurheartj/ehp297
39. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation (2009) 119(16):2250-94. doi:10.1161/CIRCULATIONAHA.109.192230
40. Sharkey SW. A Guide to Interpretation of Hemodynamic Data in the Coronary Care Unit. 1st ed. Philadelphia: Lippincott, Williams, and Wilkins (1997)
41. Humbert M, Gerry Coghlan J, Khanna D. Early detection and management of pulmonary arterial hypertension. Eur Respir Rev (2012) 21(126):306-12. doi:10.1183/09059180.00005112
42. Bossone E, D'Andrea A, D'Alto M, Citro R, Argiento P, Ferrara F, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. J Am Soc Echocardiogr (2013) 26(1):1-14. doi:10.1016/j.echo.2012.10.009
43. Forfia PR, Vachiéry JL. Echocardiography in pulmonary arterial hypertension. Am J Cardiol (2012) 110(6 Suppl):16S-24S. doi:10.1016/j.amjcard.2012.06.012
44. Habib G, Torbicki A. The role of echocardiography in the diagnosis and management of patients with pulmonary hypertension. Eur Respir Rev (2010) 19(118):288-99. doi:10.1183/09059180.00008110
45. Mathai SC, Sibley CT, Forfia PR, Mudd JO, Fisher MR, Tedford RJ, et al. Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. J Rheumatol (2011) 38(11):2410-8. doi:10.3899/jrheum.110512
46. Takatsuki S, Nakayama T, Jone PN, Wagner BD, Naoi K, Ivy DD, et al. Tissue Doppler imaging predicts adverse outcome in children with idiopathic pulmonary arterial hypertension. J Pediatr (2012) 161(6):1126-31. doi:10.1016/j.jpeds.2012.05.050
47. Rajagopalan N, Simon MA, Mathier MA, López-Candales A. Identifying right ventricular dysfunction with tissue Doppler imaging in pulmonary hypertension. Int J Cardiol (2008) 128(3):359-63. doi:10.1016/j.ijcard.2007.06.094
48. Huez S, Vachiéry JL, Unger P, Brimioulle S, Naeije R. Tissue Doppler imaging evaluation of cardiac adaptation to severe pulmonary hypertension. Am J Cardiol (2007) 100(9):1473-8. doi:10.1016/j.amjcard.2007.06.047
49. Gurudevan SV, Malouf PJ, Kahn AM, Auger WR, Waltman TJ, Madani M, et al. Noninvasive assessment of pulmonary vascular resistance using Doppler tissue imaging of the tricuspid annulus. J Am Soc Echocardiogr (2007) 20(10):1167-71. doi:10.1016/j.echo.2007.02.004
50. Devaraj A, Hansell DM. Computed tomography signs of pulmonary hypertension: old and new observations. Clin Radiol (2009) 64(8):751-60. doi:10.1016/j.crad.2008.12.005
51. Grosse C, Grosse A. CT findings in diseases associated with pulmonary hypertension: a current review. Radiographics (2010) 30(7):1753-77. doi:10.1148/rg.307105710
52. Devaraj A, Wells AU, Meister MG, Corte TJ, Wort SJ, Hansell DM. Detection of pulmonary hypertension with multidetector CT and echocardiography alone and in combination. Radiology (2010) 254(2):609-16. doi:10.1148/radiol.09090548
53. Boerrigter B, Mauritz GJ, Marcus JT, Helderman F, Postmus PE, Westerhof N, et al. Progressive dilatation of the main pulmonary artery is a characteristic of pulmonary arterial hypertension and is not related to changes in pressure. Chest (2010) 138(6):1395-401. doi:10.1378/chest.10-0363
54. Revel MP, Faivre JB, Remy-Jardin M, Delannoy-Deken V, Duhamel A, Remy J. Pulmonary hypertension: ECG-gated 64-section CT angiographic evaluation of new functional parameters as diagnostic criteria. Radiology (2009) 250(2):558-66. doi:10.1148/radiol.2502080315
55. Katzberg RW, Haller C. Contrast-induced nephrotoxicity: clinical landscape. Kidney Int Suppl (2006) 69(100):S3-7. doi:10.1038/sj.ki.5000366
56. Suga K. Pulmonary function-morphologic relationships assessed by SPECT-CT fusion images. Ann Nucl Med (2012) 26(4):298-310. doi:10.1007/s12149-012-0576-5
57. Zöphel K, Bacher-Stier C, Pinkert J, Kropp J. Ventilation/perfusion lung scintigraphy: what is still needed? A review considering technetium-99m-labeled macro-aggregates of albumin. Ann Nucl Med (2009) 23(1):1-16. doi:10.1007/s12149-008-0187-3
58. Paffett ML, Hesterman J, Candelaria G, Lucas S, Anderson T, Irwin D, et al. Longitudinal in vivo SPECT/CT imaging reveals morphological changes and cardiopulmonary apoptosis in a rodent model of pulmonary arterial hypertension. PLoS One (2012) 7(7):e40910. doi:10.1371/journal.pone.0040910
59. Lundgrin EL, Park MM, Sharp J, Tang WH, Thomas JD, Asosingh K, et al. Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. Ann Am Thorac Soc (2013) 10(1):1-9. doi:10.1513/AnnalsATS.201206-029OC
60. Wang L, Zhang Y, Yan C, He J, Xiong C, Zhao S, et al. Evaluation of right ventricular volume and ejection fraction by gated (18)F-FDG PET in patients with pulmonary hypertension: comparison with cardiac MRI and CT. J Nucl Cardiol (2013) 20(2):242-52. doi:10.1007/s12350-013-9672-8
61. Fang W, Zhao L, Xiong CM, Ni XH, He ZX, He JG, et al. Comparison of 18F-FDG uptake by right ventricular myocardium in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease. Pulm Circ (2012) 2(3):365-72. doi:10.4103/2045-8932.101651
62. Hagan G, Southwood M, Treacy C, Ross RM, Soon E, Coulson J, et al. (18)FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: a proof-of-principle study. Pulm Circ (2011) 1(4):448-55. doi:10.4103/2045-8932.93543
63. Marsboom G, Wietholt C, Haney CR, Toth PT, Ryan JJ, Morrow E, et al. Lung 18F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 185(6):670-9. doi:10.1164/rccm.201108-1562OC
64. Fahey FH, Treves ST, Adelstein SJ. Minimizing and communicating radiation risk in pediatric nuclear medicine. J Nucl Med Technol (2012) 40(1):13-24. doi:10.2967/jnumed.109.069609
65. Hoeper MM, Tongers J, Leppert A, Baus S, Maier R, Lotz J. Evaluation of right ventricular performance with a right ventricular ejection fraction thermodilution catheter and MRI in patients with pulmonary hypertension. Chest (2001) 120:502-7. doi:10.1378/chest.120.2.502
66. Roeleveld RJ, Vonk-Noordegraaf A, Marcus JT, Bronzwaer JG, Marques KM, Postmus PE, et al. Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. Chest (2004) 125:572-9. doi:10.1378/chest.125.2.572
67. Vonk-Noordegraaf A, Marcus JT, Holverda S, Roseboom B, Postmus PE. Early changes of cardiac structure and function in COPD patients with mild hypoxemia. Chest (2005) 127:1898-903. doi:10.1378/chest.127.6.1898
68. Vonk-Noordegraaf A, Marcus JT, Roseboom B, Postmus PE, Faes TJ, de Vries PM. The effect of right ventricular hypertrophy on left ventricular ejection fraction in pulmonary emphysema. Chest (1997) 112:640-5. doi:10.1378/chest.112.3.640
69. van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronzwaer JG, Spreeuwenberg MD, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J (2007) 28:1250-7. doi:10.1093/eurheartj/ehl477
70. Dimitroulas T, Mavrogeni S, Kitas GD. Imaging modalities for the diagnosis of pulmonary hypertension in systemic sclerosis. Nat Rev Rheumatol (2012) 8(4):203-13. doi:10.1038/nrrheum.2012.2
71. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J (2004) 147(2):218-23. doi:10.1016/j.ahj.2003.10.005
72. Surie S, Reesink HJ, Marcus JT, van der Plas MN, Kloek JJ, Vonk-Noordegraaf A, et al. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension. Clin Cardiol (2013) 36(11):698-703. doi:10.1002/clc.22197
73. Blalock S, Chan F, Rosenthal D, Ogawa M, Maxey D, Feinstein J. Magnetic resonance imaging of the right ventricle in pediatric pulmonary arterial hypertension. Pulm Circ (2013) 3(2):350-5. doi:10.4103/2045-8932.114763
74. Ibrahim el SH, White RD. Cardiovascular magnetic resonance for the assessment of pulmonary arterial hypertension: toward a comprehensive CMR exam. Magn Reson Imaging (2012) 30(8):1047-58. doi:10.1016/j.mri.2012.03.001
75. Hopkins SR, Wielpütz MO, Kauczor HU. Imaging lung perfusion. J Appl Physiol (1985) (2012) 113(2):328-39. doi:10.1152/japplphysiol.00320.2012
76. Moledina S, Pandya B, Bartsota M, Mortensen KH, McMillan M, Quyam S, et al. Prognostic significance of cardiac magnetic resonance imaging in children with pulmonary hypertension. Circ Cardiovasc Imaging (2013) 6(3):407-14. doi:10.1161/CIRCIMAGING.112.000082
77. Singhal S, Achary S, Mahajan S, Wanjari A, Agarwal A. Stem cells and lung diseases. J Assoc Physicians India (2011) 59:433-6
78. Duong HT, Erzurum SC, Asosingh K. Pro-angiogenic hematopoietic progenitor cells and endothelial colony-forming cells in pathological angiogenesis of bronchial and pulmonary circulation. Angiogenesis (2011) 14(4):411-22. doi:10.1007/s10456-011-9228-y
79. Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med (2001) 22(3):405-18. doi:10.1016/S0272-5231(05)70280-X
80. Smadja DM, Gaussem P, Mauge L, Israël-Biet D, Dignat-George F, Peyrard S, et al. Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation (2009) 119(3):374-81. doi:10.1161/CIRCULATIONAHA.108.808246
81. Fadini GP, Avogaro A, Ferraccioli G, Agostini C. Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications. Eur Respir J (2010) 35(2):418-25. doi:10.1183/09031936.00112809
82. Amabile N, Guignabert C, Montani D, Yeghiazarians Y, Boulanger CM, Humbert M. Cellular microparticles in the pathogenesis of pulmonary hypertension. Eur Respir J (2013) 42(1):272-9. doi:10.1183/09031936.00087212
83. Levy M, Bonnet D, Mauge L, Celermajer DS, Gaussem P, Smadja DM. Circulating endothelial cells in refractory pulmonary hypertension in children: markers of treatment efficacy and clinical worsening. PLoS One (2013) 8(6):e65114. doi:10.1371/journal.pone.0065114
84. Smadja DM, Gaussem P, Mauge L, Lacroix R, Gandrille S, Remones V, et al. Comparison of endothelial biomarkers according to reversibility of pulmonary hypertension secondary to congenital heart disease. Pediatr Cardiol (2010) 31(5):657-62. doi:10.1007/s00246-010-9674-0
85. Smadja DM, Mauge L, Gaussem P, d'Audigier C, Israel-Biet D, Celermajer DS, et al. Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. Angiogenesis (2011) 14(1):17-27. doi:10.1007/s10456-010-9192-y
86. Schiavon M, Fadini GP, Lunardi F, Agostini C, Boscaro E, Calabrese F, et al. Increased tissue endothelial progenitor cells in end-stage lung diseases with pulmonary hypertension. J Heart Lung Transplant (2012) 31(9):1025-30. doi:10.1016/j.healun.2012.06.005
87. Tantawy AA, Adly AA, Ismail EA, Habeeb NM. Flow cytometric assessment of circulating platelet and erythrocytes microparticles in young thalassemia major patients: relation to pulmonary hypertension and aortic wall stiffness. Eur J Haematol (2013) 90(6):508-18. doi:10.1111/ejh.12108
88. Visovatti SH, Hyman MC, Bouis D, Neubig R, McLaughlin VV, Pinsky DJ. Increased CD39 nucleotidase activity on microparticles from patients with idiopathic pulmonary arterial hypertension. PLoS One (2012) 7(7):e40829. doi:10.1371/journal.pone.0040829
89. Edwards AL, Gunningham SP, Clare GC, Hayman MW, Smith M, Frampton CM, et al. Professional killer cell deficiencies and decreased survival in pulmonary arterial hypertension. Respirology (2013) 18(8):1271-7. doi:10.1111/resp.12152
90. Perros F, Cohen-Kaminsky S, Gambaryan N, Girerd B, Raymond N, Klingelschmitt I, et al. Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. Am J Respir Crit Care Med (2013) 187(2):189-96. doi:10.1164/rccm.201208-1364OC
91. Lenna S, Farina AG, Martyanov V, Christmann RB, Wood TA, Farber HW, et al. Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension. Arthritis Rheum (2013) 65(5):1357-66. doi:10.1002/art.37891
92. Yeager ME, Belchenko DD, Nguyen CM, Colvin KL, Ivy DD, Stenmark KR. Endothelin-1, the unfolded protein response, and persistent inflammation: role of pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol (2012) 46(1):14-22. doi:10.1165/rcmb.2010-0506OC
93. Yeager ME, Nguyen CM, Belchenko DD, Colvin KL, Takatsuki S, Ivy DD, et al. Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. Eur Respir J (2012) 39(1):104-11. doi:10.1183/09031936.00072311
94. Yeager ME, Nguyen CM, Belchenko DD, Colvin KL, Takatsuki S, Ivy DD, et al. Circulating myeloid-derived suppressor cells are increased and activated in pulmonary hypertension. Chest (2012) 141(4):944-52. doi:10.1378/chest.11-0205
95. Dereddy N, Huang J, Erb M, Guzel S, Wolk JH, Sett SS, et al. Associated inflammation or increased flow-mediated shear stress, but not pressure alone, disrupts endothelial caveolin-1 in infants with pulmonary hypertension. Pulm Circ (2012) 2(4):492-500. doi:10.4103/2045-8932.105038
96. Morice AH, Pepke-Zaba J, Brown MJ, Thomas PS, Higenbottam TW. Atrial natriuretic peptide in primary pulmonary hypertension. Eur Respir J (1990) 3(8):910-3
97. Hall S, Brogan P, Haworth SG, Klein N. Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children. Thorax (2009) 64(9):778-83. doi:10.1136/thx.2008.106435
98. Bernus A, Wagner BD, Accurso F, Doran A, Kaess H, Ivy DD. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest (2009) 135(3):745-51. doi:10.1378/chest.08-0187
99. Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol (2009) 135(1):21-6. doi:10.1016/j.ijcard.2008.03.009
100. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest (2006) 129(5):1313-21. doi:10.1378/chest.129.5.1313
101. Souza R, Jardim C, Julio Cesar Fernandes C, Silveira Lapa M, Rabelo R, Humbert M. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med (2007) 101(1):69-75. doi:10.1016/j.rmed.2006.04.014
102. Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation (2003) 108(7):844-8. doi:10.1161/01.CIR.0000084544.54513.E2
103. Lassus P, Turanlahti M, Heikkilä P, Andersson LC, Nupponen I, Sarnesto A, et al. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med (2001) 164(10 Pt 1):1981-7. doi:10.1164/ajrccm.164.10.2012036
104. Duncan M, Wagner BD, Murray K, Allen J, Colvin K, Accurso FJ, et al. Circulating cytokines and growth factors in pediatric pulmonary hypertension. Mediators Inflamm (2012) 2012:143428. doi:10.1155/2012/143428
105. Yeager ME, Colvin KL, Everett AD, Stenmark KR, Ivy DD. Plasma proteomics of differential outcome to long-term therapy in children with idiopathic pulmonary arterial hypertension. Proteomics Clin Appl (2012) 6(5-6):257-67. doi:10.1002/prca.201100078
106. Nickel N, Kempf T, Tapken H, Tongers J, Laenger F, Lehmann U, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 178(5):534-41. doi:10.1164/rccm.200802-235OC
107. Davie NJ, Schermuly RT, Weissmann N, Grimminger F, Ghofrani HA. The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. Eur J Clin Invest (2009) 39(Suppl 2):38-49. doi:10.1111/j.1365-2362.2009.02120.x
108. Kwon YS, Chi SY, Shin HJ, Kim EY, Yoon BK, Ban HJ, et al. Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. J Korean Med Sci (2010) 25(10):1487-91. doi:10.3346/jkms.2010.25.10.1487
109. Farha S, Sharp J, Asosingh K, Park M, Comhair SA, Tang WH, et al. Mast cell number, phenotype, and function in human pulmonary arterial hypertension. Pulm Circ (2012) 2(2):220-8. doi:10.4103/2045-8932.97609
110. Sungprem K, Khongphatthanayothin A, Kiettisanpipop P, Chotivitayatarakorn P, Poovorawan Y, Lertsapcharoen P. Serum level of soluble intercellular adhesion molecule-1 correlates with pulmonary arterial pressure in children with congenital heart disease. Pediatr Cardiol (2009) 30(4):472-6. doi:10.1007/s00246-008-9374-1
111. Geraci M, Meyrick B. Genomics and proteomics of pulmonary vascular disease. Compr Physiol (2011) 1(1):467-83. doi:10.1002/cphy.c100031
112. Demir M, Uyan U, Keceoclu S, Demir C. The relationship between vitamin D deficiency and pulmonary hypertension. Prague Med Rep (2013) 114(3):154-61
113. Henkens IR, Hazenoot T, Boonstra A, Huisman MV, Vonk-Noordegraaf A. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Eur Respir J (2013) 41(4):872-8. doi:10.1183/09031936.00039212
114. Iodice FG, Di Chiara L, Boenzi S, Aiello C, Monti L, Cogo P, et al. Cobalamin C defect presenting with isolated pulmonary hypertension. Pediatrics (2013) 132(1):e248-51. doi:10.1542/peds.2012-1945
115. Park JH, Lee JH, Jeong JO, Seong IW, Choi SW. Thiamine deficiency as a rare cause of reversible severe pulmonary hypertension. Int J Cardiol (2007) 121(1):e1-3. doi:10.1016/j.ijcard.2006.08.054
116. Rao SN, Chandak GR. Cardiac beriberi: often a missed diagnosis. J Trop Pediatr (2010) 56(4):284-5. doi:10.1093/tropej/fmp108
117. Kupari M, Rapola J. Reversible pulmonary hypertension associated with vitamin C deficiency. Chest (2012) 142(1):225-7. doi:10.1378/chest.11-1857
118. Bogaard HJ, Mizuno S, Guignabert C, Al Hussaini AA, Farkas D, Ruiter G, et al. Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans. Am J Respir Cell Mol Biol (2012) 46(5):582-91. doi:10.1165/rcmb.2011-0296OC
119. Rhodes CJ, Wharton J, Howard L, Gibbs JS, Vonk-Noordegraaf A, Wilkins MR. Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. Eur Respir J (2011) 38(6):1453-60. doi:10.1183/09031936.00037711
120. Hampole CV, Mehrotra AK, Thenappan T, Gomberg-Maitland M, Shah SJ. Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. Am J Cardiol (2009) 104(6):868-72. doi:10.1016/j.amjcard.2009.05.016
121. Preston IR, Tang G, Tilan JU, Hill NS, Suzuki YJ. Retinoids and pulmonary hypertension. Circulation (2005) 111(6):782-90. doi:10.1161/01.CIR.0000155254.86840.47
122. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 116(2):281-97. doi:10.1016/S0092-8674(04)00045-5
123. Rupani H, Sanchez-Elsner T, Howarth P. MicroRNAs and respiratory diseases. Eur Respir J (2013) 41(3):695-705. doi:10.1183/09031936.00212011
124. Xu J, Zhao J, Evan G, Xiao C, Cheng Y, Xiao J. Circulating microRNAs: novel biomarkers for cardiovascular diseases. J Mol Med (Berl) (2012) 90(8):865-75. doi:10.1007/s00109-011-0840-5
125. Wei C, Henderson H, Spradley C, Li L, Kim IK, Kumar S, et al. Circulating miRNAs as potential marker for pulmonary hypertension. PLoS One (2013) 8(5):e64396. doi:10.1371/journal.pone.0064396
126. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med (2011) 208(3):535-48. doi:10.1084/jem.20101812
127. Yang S, Banerjee S, Freitas AD, Cui H, Xie N, Abraham E, et al. miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol (2012) 302(6):L521-9. doi:10.1152/ajplung.00316.2011
128. Pauling L, Robinson AB, Teranishi R, Cary P. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc Natl Acad Sci U S A (1971) 68(10):2374-6. doi:10.1073/pnas.68.10.2374
129. Phillips M. Breath tests in medicine. Sci Am (1992) 267(1):74-9. doi:10.1038/scientificamerican0792-74
130. Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest (2010) 138(3):682-92. doi:10.1378/chest.09-2090
131. Abman SH. Inhaled nitric oxide for the treatment of pulmonary arterial hypertension. Handb Exp Pharmacol (2013) 218:257-76. doi:10.1007/978-3-642-38664-0_11
132. van de Kant KD, van der Sande LJ, Jöbsis Q, van Schayck OC, Dompeling E. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review. Respir Res (2012) 13:117. doi:10.1186/1465-9921-13-117
133. Stuber T, Sartori C, Salmòn CS, Hutter D, Thalmann S, Turini P, et al. Respiratory nitric oxide and pulmonary artery pressure in children of Aymara and European ancestry at high altitude. Chest (2008) 134(5):996-1000. doi:10.1378/chest.08-0854
134. Dweik RA, Laskowski D, Abu-Soud HM, Kaneko F, Hutte R, Stuehr DJ, et al. Nitric oxide synthesis in the lung. Regulation by oxygen through a kinetic mechanism. J Clin Invest (1998) 1013:660-6. doi:10.1172/JCI1378
135. Ozkan M, Dweik RA, Laskowski D, Arroliga AC, Erzurum SC. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. Lung (2001) 1794:233-43. doi:10.1007/s004080000064
136. Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis (2007) 6611:1467-72. doi:10.1136/ard.2007.069609
137. Böger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med (2006) 38:126-36. doi:10.1080/07853890500472151
138. Kielstein JT, Bode-Böger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol (2005) 25(7):1414-8. doi:10.1161/01.ATV.0000168414.06853.f0
139. Skoro-Sajer N, Mittermayer F, Panzenboeck A, Bonderman D, Sadushi R, Hitsch R, et al. Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med (2007) 176(11):1154-60. doi:10.1164/rccm.200702-278OC
140. Sanli C, Oguz D, Olgunturk R, Tunaoglu FS, Kula S, Pasaoglu H, et al. Elevated homocysteine and asymmetric dimethyl arginine levels in pulmonary hypertension associated with congenital heart disease. Pediatr Cardiol (2012) 33(8):1323-31. doi:10.1007/s00246-012-0321-9
141. El-Shanshory M, Badraia I, Donia A, Abd El-Hameed F, Mabrouk M. Asymmetric dimethylarginine levels in children with sickle cell disease and its correlation to tricuspid regurgitant jet velocity. Eur J Haematol (2013) 91(1):55-61. doi:10.1111/ejh.12114
142. Schuster A, Thakur A, Wang Z, Borowski AG, Thomas JD, Tang WH. Increased exhaled nitric oxide levels after exercise in patients with chronic systolic heart failure with pulmonary venous hypertension. J Card Fail (2012) 18(10):799-803. doi:10.1016/j.cardfail.2012.08.356
143. Cikach FS Jr, Tonelli AR, Barnes J, Paschke K, Newman J, Grove D, et al. Breath analysis in pulmonary arterial hypertension. Chest (2013). doi:10.1378/chest.13-1363
144. Warwick G, Kotlyar E, Chow S, Thomas PS, Yates DH. Exhaled breath condensate in pulmonary arterial hypertension. J Breath Res (2012) 6(3):036006. doi:10.1088/1752-7155/6/3/036006
145. Cracowski JL, Degano B, Chabot F, Labarère J, Schwedhelm E, Monneret D, et al. Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. Chest (2012) 142(4):869-76. doi:10.1378/chest.11-1267
146. Bogdan M, Humbert M, Francoual J, Claise C, Duroux P, Simonneau G, et al. Urinary cGMP concentrations in severe primary pulmonary hypertension. Thorax (1998) 53(12):1059-62. doi:10.1136/thx.53.12.1059
147. Ivy DD, Abman SH, Barst RJ, Berger RM, Bonnet D, Fleming TR, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol 2013 62(25 Suppl):D117-26